Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronica Bunn

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.
Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.
Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Pageof 2